SANYA, China — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia, the second LPGA title for the young Japanese. The ...
Ayden Heaven merits a full debut. Casemiro should be saved for the Real Sociedad second leg (unless Manuel Ugarte is fit) and Toby Collyer was bright during his cameo in San Sebastian and United ...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...
Business Wire India − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints wer... "Lorem ...
The statement is a little confusing, because Ayden Heaven also left Arsenal in the same seasonal year, and while penciled in immediately as a first team signing, Chido Obi actually made his first team ...
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA … ...
Arsenal bid farewell to Hale End duo Ayden Heaven and Chido Obi in 2024/25 as the two talents joined Manchester United. After Obi made waves in the Arsenal academy, there was uncertainty regarding his ...
Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist ...
The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those who received placebo ...
These patients may experience a high treatment burden, and severe symptoms can impact their quality of life,” said Andy Plump, M.D., Ph.D., President of R&D at Takeda. “We are deeply committed ...
Credit: Orawan Pattarawimonchai / Shutterstock. Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide as an add-on to standard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback